Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping

Rhea-AI Summary

Bionano (Nasdaq: BNGO) announced Bionano Symposium 2026, a free virtual event Feb 23-26, 2026 showcasing optical genome mapping (OGM) research and applications.

The four-day program features >30 international researchers, sessions on oncology, hematologic malignancies, constitutional genetics, bioprocessing, and demonstrations of Ionic, Saphyr, Stratys, and VIA.

Key Figures

Symposium dates: February 23–26, 2026 Event duration: Four days Presenting researchers: Over 30 researchers +5 more

8 metrics

Symposium dates February 23–26, 2026 Bionano Symposium 2026 schedule

Event duration Four days Length of Bionano Symposium 2026

Presenting researchers Over 30 researchers Speakers from North America, Europe, and Asia

Daily start time 7:00 AM PST Each symposium session start time

Session length Approximately three hours Duration of each daily session

Current price $1.15 Pre-news market context for BNGO

52-week high $6.315 BNGO 52-week trading range

52-week low $1.06 BNGO 52-week trading range

Market Reality Check

Price: $1.15 Vol: Volume 281,167 is slightl...

normal vol

$1.15 Last Close

Volume Volume 281,167 is slightly below the 20-day average of 313,158 (relative volume 0.9). normal

Technical Price at $1.15 is trading below the 200-day MA of $2.63 and far below the $6.315 52-week high.

Peers on Argus

BNGO was up 2.22% while key peers were mixed: HBIO +2.53%, NXGL +4.53%, but RVP ...

BNGO was up 2.22% while key peers were mixed: HBIO +2.53%, NXGL +4.53%, but RVP -3.34%, FEMY -0.57%, MHUA -27.18%. This pattern points to a stock-specific move rather than a unified sector trend.

Historical Context

5 past events · Latest: Feb 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	Gene-editing OGM study	Positive	-1.3%	Peer-reviewed study showed OGM detecting low-frequency gene editing alterations.
Jan 12	Preliminary FY2025 results	Negative	+0.6%	Preliminary Q4 and FY2025 revenue declined year-over-year with updated metrics.
Dec 11	AMP 2025 OGM recap	Positive	-1.2%	Conference recap showed broader OGM use across multiple disease areas and workflows.
Dec 03	OGM reimbursement update	Positive	+3.0%	CMS increased CPT code 81195 payment by 47% for OGM in hematologic malignancies.
Nov 13	Q3 2025 earnings	Positive	-8.1%	Q3 revenue grew with higher gross margin and lower operating expenses versus prior year.

Pattern Detected

Across recent news, BNGO more often showed price moves that diverged from the apparent sentiment of announcements, with only one clearly aligned reaction.

Recent Company History

Over the past few months, Bionano has reported multiple updates around optical genome mapping (OGM) and its business. A November 10-Q showed higher revenue but liquidity concerns, followed by Q3 2025 earnings on Nov 13 with revenue of $7.4M and reduced operating expenses. In December, CMS raised OGM CPT code 81195 payment by 47%, and AMP 2025 data highlighted expanded OGM applications. Early 2026 saw preliminary FY2025 results and a study on OGM for gene-editing QC. Today’s symposium announcement continues this stream of OGM adoption and awareness news.

Market Pulse Summary

This announcement details Bionano Symposium 2026, a four-day virtual event from February 23–26, 2026...

Analysis

This announcement details Bionano Symposium 2026, a four-day virtual event from February 23–26, 2026 featuring over 30 researchers presenting on optical genome mapping in oncology, constitutional genetics, and bioprocessing. It reinforces Bionano’s role at the center of the OGM community and highlights customer use of Ionic, Saphyr, Stratys, and VIA. Against a backdrop of recent reimbursement gains and clinical data, investors may watch how such educational efforts translate into system placements, consumable usage, and longer-term revenue trends.

Key Terms

optical genome mapping, cytogenetic, structural variants, hematologic malignancies, +4 more

8 terms

optical genome mapping medical

"global event for the optical genome mapping (OGM) community"

Optical genome mapping is a laboratory technique that produces a high-resolution picture of a person’s long DNA strands to find large structural changes such as missing, extra, or rearranged pieces. For investors, it matters because the method can improve diagnosis, speed development of genetic tests and therapies, and influence regulatory approvals and market demand for companies offering more accurate or faster genomic tools — think of it as a wide-angle camera that reveals large-scale defects traditional microscopes might miss.

cytogenetic medical

"hear how cytogenetic labs and key opinion leaders (KOLs) worldwide"

Relating to the study of cells’ chromosomes — the bundled packages of DNA that act like a building’s blueprint for traits and behavior. Cytogenetic information shows whether those blueprints have missing, extra, or rearranged pieces, which can affect disease diagnosis, how patients respond to treatments, and whether a therapy is safe; for investors, that data can influence clinical trial outcomes, regulatory approval chances, and market potential.

structural variants medical

"OGM helps identify pathogenic structural variants and streamlines laboratory workflows"

Structural variants are large-scale changes in an organism’s DNA—such as missing, extra, flipped, or rearranged chunks of genetic material—that are like tearing out, duplicating, or reshuffling chapters in a book. Investors should care because these changes can drive or explain diseases, alter how well diagnostics and therapies work, and shift the commercial and regulatory outlook for drugs, tests, and gene-based treatments.

hematologic malignancies medical

"covering research applications in hematologic malignancies, solid tumors"

Hematologic malignancies are types of cancers that start in the blood or the organs responsible for blood production, like the bone marrow and lymph nodes. They matter because they can disrupt normal blood functions, leading to issues like weakness, infections, or abnormal growths, and often require specialized treatments.

cell and gene therapy medical

"quality control tool for cell and gene therapy applications"

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

ffpe medical

"KOLs ... will discuss FFPE DNA isolation for downstream NGS"

FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.

ngs technical

"FFPE DNA isolation for downstream NGS, semi-automated ultra-high"

A laboratory method that reads large amounts of DNA or RNA quickly to identify genetic differences, mutations, or microbes, similar to scanning many pages of a book at once to find important words. Investors care because it drives diagnostics, drug discovery and personalized treatments, can create recurring revenue from testing services and instruments, and influences regulatory approvals, partnerships and market value in biotech and healthcare companies.

cpt code regulatory

"Category I CPT code for OGM use in hematologic malignancies"

A CPT code is a standardized numeric label used by healthcare providers and insurers to identify medical procedures, tests, and services for billing and reimbursement. Think of it as a SKU or price tag for each clinical service: which code is used and how it’s reimbursed directly affects a provider’s revenue and a medical product’s market adoption, so investors watch codes and payment rules to estimate financial impact.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium provides a unique platform for researchers to present cutting-edge findings and share insights into emerging applications of OGM technology.

Join leading scientists from around the world as they highlight breakthroughs in OGM from February 23-26, 2026. The four-day event will feature presentations from over 30 researchers across North America, Europe, and Asia, covering research applications in hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy. The virtual program includes scientific presentations, interactive panel discussions with Q&A, and a virtual poster hall.

"At Bionano, we are transforming the way the world sees the genome," said Erik Holmlin, president and chief executive officer of Bionano. "Our Symposium brings together the global OGM community to share real-world experiences and demonstrate how OGM can reveal genomic complexity that is difficult to detect with conventional technologies. The 2026 program highlights the expanding role of OGM in oncology research, constitutional genetics, and bioprocessing.”

“We provide the technology, and scientists continue to redefine what’s possible with it,” said Alka Chaubey, PhD, FACMG, chief medical officer at Bionano. “The 2026 Symposium will showcase how researchers worldwide are advancing genome analysis through innovative applications of OGM and establishing it as a cornerstone tool for modern cytogenetic and genome analysis.”

Each session will begin at 7:00 AM PST and last approximately three hours, opening with a technology introduction and brief remarks from Dr. Chaubey and followed by presentations from invited external speakers, a live panel discussion and Q&A. Attendees can also explore scientific posters within the virtual platform throughout the event.

Symposium 2026 Overview:

• Monday, February 23: Advancements in Hematologic Malignancies with OGM
  From leukemias to lymphomas and myelomas, hear how cytogenetic labs and key opinion leaders (KOLs) worldwide are implementing OGM across multiple research applications. Experts will share insights on workflow performance compared to traditional cytogenetic and molecular methods, highlighting OGM’s precision, sensitivity, and discuss how OGM helps identify pathogenic structural variants and streamlines laboratory workflows.
  
  
  • Ravindra Kolhe, MD, PhD, FACP – Augusta University, USA
  • Wahab A. Khan, PhD, FACMG – Dartmouth-Hitchcock Medical Center, USA
  • Amber Verhasselt - KU Leuven, Belgium
  • Klaudia Starosz- Medical University of Lodz, Poland
  • Gokce A. Toruner, MD, PhD, FACMG – The University of Texas MD Anderson Cancer Center, USA
  • Elly De Vlieghere, PhD, MSc - AZ Sint-Jan Brugge, Belgium
  • Anna Maria Puiggros Metje - Hospital del Mar, Spain
  • Rashmi Kanagal Shamanna, MD - The University of Texas MD Anderson Cancer Center, USA
    
    

• Tuesday, February 24: New Frontiers in Oncology Research and Bioprocessing Applications
  Discover how OGM can reveal pathogenic and driver structural variants in challenging indications, including multiple myeloma, lymphomas, and solid tumors. Learn how OGM is also being used as a genome integrity quality control tool for cell and gene therapy applications.
  
  
  • Hippolyte Guerineau, PharmD - Centre Hospitalier de Versailles, France
  • Agnes Daudignon, PhD - CHU de Lille, France
  • Ying S. Zou, MD, PhD, FACMG - Johns Hopkins University School of Medicine, USA
  • Alejandro Berenguer Rubio, MD - Instituto de Investigación Sanitaria La Fe (IIS La Fe), Spain
  • Darren "Ben" Finlay, PhD - Sanford Burnham Prebys Medical Discovery Institute, USA
  • James Haldane – iPSC Platform bit.bio, UK
  • Annelise Bennaceur Griscelli – CiTHERA- Center for iPS Cell Therapies, France
  • Marc-Henri Stern, MD PhD - Institut Curie, France
    
  • Phillip D. Michaels, MD - Brigham and Women’s Hospital and Harvard University, USA
  • Adrian Dubuc, PhD, FACMG - Roswell Park Comprehensive Cancer Center, USA
    
    

• Wednesday, February 25: OGM Making Its Mark in Constitutional Genetic Disorder Research
  Speakers will share experiences using OGM to uncover structural variants in rare and unresolved genetic disorders, developmental disorders, and reproductive conditions, including recurrent pregnancy loss.
  
  
  • Yassmine Akkari, PhD, FACMG - Nationwide Children's Hospital, USA
  • Debopriya Chakraborty - Dartmouth-Hitchcock Medical Center, USA
  • Walaa Darwiche, PhD - CHU Amiens – Picardie, France
  • Li Fu, MD - Yokohama City University Graduate School of Medicine, Japan
  • Laila El Khattabi, PhD, PharmD - Sorbonne University APHP Hospitals and Paris Brain Institute, France
  • Karthik Bharadwaj Tallapaka, MD, DrNB - Centre for Cellular and Molecular Biology, India
  • Bruna Burssed, MSc - Universidade Federal de São Paulo (UNIFESP), Brazil and Radboud University Medical Center, The Netherlands
  • Mehmet Burak Mutlu, MD - Detagen Genetic Diseases Diagnosis and Evaluation Center, Turkey
  • Nikhil Sahajpal, PhD, FACMG - Greenwood Genetic Center, USA
    
    

• Thursday, February 26: Genome Analysis Landscape with Bionano Products: Ionic®, Saphyr®, and Stratys™ systems, and VIA™ software
  Learn directly from customers about Bionano tools, including Ionic, Saphyr, and Stratys systems, and VIA software. KOLs from the US, Canada, and Netherlands will discuss FFPE DNA isolation for downstream NGS, semi-automated ultra-high molecular DNA isolation for OGM, high-throughput Stratys applications, and a live demo of VIA software for analysis of hematologic malignancies.
  
  
  • Alex Hoischen, PhD - Radboud University Medical Center, The Netherlands
  • Chantal Courtemanche, PhD - CHU de Québec, Canada
  • Vineet Bafna, PhD –University of California San Diego, USA
  • Brandon M. Shaw, PhD, FACMG, DABMGG –Henry Ford Health System, USA
  • Elizabeth McCready, PhD, PCCMG - Hamilton Health Sciences Center, Canada
  • Eddy N De Boer - University Medical Centre Groningen, The Netherlands
  • Arjan Buijs - University Medical Centre Groningen, The Netherlands
  • Adam C. Smith, PhD, FCCMG, FACMG, erCLG – Labcorp, USA
    
    

Registration is free and open to all. Secure your spot today at: www.bionano.com/symposium-2026/

Showcase your work to the global OGM community! Submit your poster here: https://bionanosymposium2026.vfairs.com/en/poster-submission

About Bionano Genomics

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things; the ability and utility of OGM for research applications in hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy; the ability and utility of OGM as a genomic analysis tool in the applications presented in Symposium 2026; the ability and utility of OGM to reveal genomic complexity that is difficult to detect with conventional technologies; the impact of Symposium 2026 to advance our commercial goals including market development and OGM adoption; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; and any other statements that are not of historical fact. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM to be useful for research applications in hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy; the failure OGM to be a useful genomic analysis tool in the applications presented in Symposium 2026; the failure of OGM to reveal genomic complexity that is difficult to detect with conventional technologies; the failure of Symposium 2026 to advance our commercial goals including market development and OGM adoption; future research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies that differ or contradict the research, presentations and publications referenced in this press release and at Symposium 2026; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties including those described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com

FAQ

When is Bionano Symposium 2026 (BNGO) and what is the schedule format?

The symposium runs Feb 23-26, 2026 with daily sessions starting at 7:00 AM PST. According to Bionano, each three-hour session opens with a technology introduction, includes invited speaker presentations, a live panel with Q&A, and access to a virtual poster hall.

Which research topics will Bionano Symposium 2026 (BNGO) cover?

The event covers hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy. According to Bionano, speakers from North America, Europe, and Asia present real-world OGM applications across these research areas.

How can researchers submit a poster for Bionano Symposium 2026 (BNGO)?

Researchers can submit posters via the symposium's online portal linked on the event page. According to Bionano, poster submission is open through the virtual platform and selected posters will be available in the event's virtual poster hall throughout the symposium.

Will Bionano demonstrate products like Saphyr and VIA at Symposium 2026 (BNGO)?

Yes, product-focused sessions include Ionic, Saphyr, Stratys systems, and VIA software demonstrations. According to Bionano, Thursday's program features customer-led talks on DNA isolation workflows, high-throughput Stratys applications, and a live VIA software demo for hematologic analysis.

Is registration required and what is the cost to attend Bionano Symposium 2026 (BNGO)?

Registration is required but the event is free to attend. According to Bionano, registration is open to all and interested participants are directed to the symposium registration page to secure a spot and access virtual sessions and poster materials.

Who are the intended attendees for Bionano Symposium 2026 (BNGO) and what value will they get?

Target attendees include researchers, cytogenetic labs, and clinicians exploring OGM research applications. According to Bionano, participants will learn workflow comparisons with traditional methods, see OGM use cases in oncology and genetics, and engage in live Q&A with global experts.